Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder.
Lithium is a first-line agent for the treatment of bipolar disorder. A significant association between the Val66Met polymorphism of the brain-derived neurotrophic factor gene and bipolar disorder has been reported. We investigated whether this polymorphism is associated with the response to lithium treatment in Japanese patients with bipolar disorder. Patients had been treated with lithium carbonate for more than 1 year, and the response was retrospectively evaluated. No significant differences were found in the genotype distribution or allele frequency between responders and non-responders. Our results suggested that the brain-derived neurotrophic factor Val66Met polymorphism might not greatly contribute to the efficacy of lithium in bipolar disorder.
Takuya
T
Masui
Ryota
R
Hashimoto
Ichiro
I
Kusumi
Katsuji
K
Suzuki
Teruaki
T
Tanaka
Shin
S
Nakagawa
Tatsuyo
T
Suzuki
Nakao
N
Iwata
Norio
N
Ozaki
Tadafumi
T
Kato
Hiroshi
H
Kunugi
Tsukasa
T
Koyama
D000328:Adult; D000483:Alleles; D019943:Amino Acid Substitution; D018692:Antimanic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy / Q000235:genetics*; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics* / Q000502:physiology; D004351:Drug Resistance / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D007564:Japan; D016651:Lithium Carbonate / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D012189:Retrospective Studies
D018692:Antimanic Agents; D019208:Brain-Derived Neurotrophic Factor; D016651:Lithium Carbonate